Sangamo Therapeutics Announces Principal Financial Officer Departure and Preliminary Low Cash Balance

summarizeSummary

Sangamo Therapeutics disclosed the termination of its principal financial officer and the appointment of an interim CFO, alongside a preliminary estimate of $20.9 million in cash and cash equivalents as of year-end 2025.

check_boxKey Events · Executive and Board Changes · SGMO

• Principal Financial Officer Departs

  Prathyusha Duraibabu's employment as the company's principal financial officer terminated on February 2, 2026.

• Interim CFO Appointed

  Nikunj Jain, the company's Vice President, Finance and Corporate Controller, has been appointed Interim Chief Financial Officer and principal financial officer, effective February 3, 2026, without additional compensation for the interim role.

• Preliminary Cash Estimate Disclosed

  The company announced a preliminary estimate of approximately $20.9 million in cash and cash equivalents as of December 31, 2025, noting that this figure is unaudited and subject to material change.

auto_awesomeAnalysis · SGMO · Life Sciences

The departure of a principal financial officer is a significant executive change, particularly for a life sciences company like Sangamo Therapeutics, which often requires careful financial management and capital raising. The appointment of an internal interim CFO provides some continuity but highlights a leadership transition at a critical time. This change, coupled with the preliminary disclosure of a relatively low cash balance of $20.9 million for a company with a market capitalization of approximately $191 million, raises concerns about the company's financial runway and potential future financing needs. Investors will be watching for further details on the permanent CFO appointment and the company's strategy to manage its cash position.